top of page

COBALT

COBALT is a placebo-controlled trial investigating whether Memantine improves health and functioning for people with dementia with Lewy bodies. Memantine is already licensed to help treat symptoms in Alzheimer's disease.

Who can take part?


You may be eligible if you:


  • Are living with dementia with Lewy bodies or Parkinson’s disease dementia

  • Are aged 55 or over

  • Have a family member or friend who knows you well and can attend visits with you



Who may not be eligible?


You may not be able to take part if, in the past 5 years, you have experienced:


  • Advanced kidney disease (stage 5 chronic renal disease)

  • A history of acute or chronic pancreatitis

  • Epilepsy or a history of seizures

  • A heart attack within the last 6 months

  • Severe heart failure or uncontrolled high blood pressure


Key details


  • Length of trial: Approximately 1 year

  • Number of visits: 9 appointments

  • Trial type: Phase 3 clinical trial

Interested in Taking Part?

Interested in taking part? Contact us to enquire about our trials and find out if you may be eligible.

MARC Logo

Connect

  • Facebook
  • LinkedIn
  • Instagram

© 2026 by Memory Assessment & Research Centre. All right reserved.

Not to be reproduced in whole or in part without the permission of the copyright owner. 

Contact

Open hours: 9am - 5pm

(24 hour voicemail service is available)

Moorgreen Hospital
Botley Road, West End

Southampton, S030 3JB

United Kingdom

bottom of page